Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

NCT00501943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Avonex (Interferon beta 1a)
DRUG: Riluzole
DRUG: Placebo

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]